Owkin is building purpose-made AI agents on K Pro for Sanofi under a multi-year collaboration and five-year licence.
Sanofi wanted faster, better-informed decisions across the drug development lifecycle and more value from its R&D data. Owkin is developing autonomous agents on K Pro, its AI Scientist platform, to carry out complex R&D tasks alongside Sanofi's teams. The release gives no performance figures; it notes a five-year licence building on a 2021 partnership.
Owkin is a French AI company building biology models and the K Pro AI Scientist, working with pharma on drug positioning, trial design and pathology diagnostics.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Published by Owkin on its own site — read the original case study on owkin.com ↗
Related use cases
- 01Boehringer Ingelheim used Owkin's K Pro multi-omic reports to prioritize targets and find spatially informed patient-selection biomarkers.
- 02Epkin used Owkin's K Pro to map prostaglandin biology and design the Phase 1 strategy for OKN4395.
- 03An oncology pharma used Owkin's K Pro and MOSAIC data to triage bispecific ADC candidates in silico.
- 04Owkin's K Pro Autopilot agent proposed a KRAS G12D drug combination that widened eligible patients from about 10% to 60%.
- 05Cleveland Clinic Abu Dhabi cut cohort assembly from days or weeks to seconds with Owkin's data transformation AI and K Pro.
- 06Owkin's MesoNet model predicts mesothelioma survival from pathology images and could shrink Phase 3 trial sizes.